文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDHT PET-CT在转移性去势抵抗性前列腺癌中对计数统计与重建方案的敏感性

Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer.
PubMed 文献 · EJNMMI Res · 2019-07-30

研究在14例mCRPC患者的336个FDHT avid病灶中,评估计数减半与EARL1/EARL2重建对[18F]FDHT PET定量参数的影响;计数减半使SUVpeak(体重归一化)重复性仍≤30%,但EARL2受影响更大,SUVmax重复性趋于超过30%,病灶检出仅轻微受损。

要点

  • 计数减半使SUVpeak(体重归一化)重复性≤30%,或可接受用于疗效监测。
  • EARL2重建较EARL1更受计数减少影响,SUVmax重复性趋于超过30%。
  • 计数减半对病灶检出仅轻微损害,在mCRPC中可能无临床相关性。

核心结论

  • 将[18F]FDHT PET每床位采集时间从3分钟减至1.5分钟,SUVpeak(体重归一化)重复性仍≤30%,一般可接受用于疗效监测。
  • EARL2重建受计数减少影响更大,尤其SUVmax重复性趋于超过30%。
  • 计数减少仅轻微损害病灶检出,在mCRPC中可能无临床相关性。

研究设计与样本

  • 在14例mCRPC患者共336个FDHT avid病灶中,连续两天行全身[18F]FDHT PET-CT,注射200 MBq后45分钟采集,每床位3分钟。
  • 将列表模式数据按计数拆分为两个各含50%计数的统计独立扫描。
  • 按EARL1(4 mm体素)与EARL2(4 mm体素+PSF)指南重建,测量SUVpeak、SUVmax、SUVmean和CNR,并以重复性系数评估变异性。

主要发现

  • 计数减少使肝脏变异系数从9.0升至12.5%(EARL1)、从10.8升至13.2%(EARL2)。
  • EARL2图像的SUV较EARL1高12.0–21.7%。
  • 100%与50%计数数据的SUV高度相关(R2>0.98;斜率0.97–1.01;ICC 0.99–1.00)。
  • 扫描内重复性系数最低为SUVmean(8.5–10.6%),SUVpeak居中(12.0–16.0%),SUVmax最高(17.8–22.2%)。
  • 计数减少使所有SUV类型与归一化方式的重测方差非显著增加(p>0.05);50%计数下排除小病灶后SUVpeak的重复性系数仍<30%。

关键数值与推荐

  • 计数减少使CNR中位下降4.6%(四分位距1.2–8.7%),EARL1与EARL2图像数值相同。
  • EARL1与EARL2的肝脏变异系数在计数减少后分别由9.0%升至12.5%、由10.8%升至13.2%。
  • EARL2图像SUV较EARL1高12.0–21.7%。
  • 扫描内重复性系数:SUVmean 8.5–10.6%,SUVpeak 12.0–16.0%,SUVmax 17.8–22.2%。
  • 100%与50%计数数据SUV相关性R2>0.98、斜率0.97–1.01、ICC 0.99–1.00。

临床怎么用

  • 在mCRPC疗效监测中,可考虑将[18F]FDHT PET每床位采集时间从3分钟减至1.5分钟,SUVpeak(体重归一化)重复性仍≤30%。
  • 若采用EARL2重建,需注意计数减少对SUVmax重复性的影响,其重复性趋于超过30%。
  • 计数减少对病灶检出仅轻微损害,在mCRPC中可能无临床相关性。

局限性

  • 样本量较小(14例患者、336个病灶),结论需更大样本验证。
  • 仅使用模拟PET-CT,未在其他设备或示踪剂条件下验证。
  • 计数减少通过列表模式拆分模拟,非真实缩短采集时间的前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Whole body [18F]-fluorodihydrotestosterone positron emission tomography ([18F]FDHT PET) imaging directly targets the androgen receptor and is a promising prognostic and predictive biomarker in metastatic castration-resistant cancer (mCRPC). To optimize [18F]FDHT PET-CT for diagnostic and response assessment purposes, we assessed how count statistics and reconstruction protocol affect its accuracy, repeatability, and lesion detectability. METHODS: Whole body [18F]FDHT PET-CT scans were acquired on an analogue PET-CT on two consecutive days in 14 mCRPC patients harbouring a total of 336 FDHT-avid lesions. Images were acquired at 45 min post-injection of 200 MBq [18F]FDHT at 3 min per bed position. List-mode PET data were split on a count-wise basis, yielding two statistically independent scans with each 50% of counts. Images were reconstructed according to current EANM Research Ltd. (EARL1, 4 mm voxel) and novel EARL2 guidelines (4 mm voxel + PSF). Per lesion, we measured SUVpeak, SUVmax, SUVmean, and contrast-to-noise ratio (CNR). SUV was normalized to dose per bodyweight as well as to the parent plasma input curve integral. Variability was assessed with repeatability coefficients (RCs). RESULTS: Count reduction increased liver coefficient of variation from 9.0 to 12.5% and from 10.8 to 13.2% for EARL1 and EARL2, respectively. SUVs of EARL2 images were 12.0-21.7% higher than EARL1. SUVs of 100% and 50% count data were highly correlated (R2 > 0.98; slope = 0.97-1.01; ICC = 0.99-1.00). Intrascan variability was volume-dependent, and count reduction resulted in higher intrascan variability for EARL2 than EARL1 images. Intrascan RCs were lowest for SUVmean (8.5-10.6%), intermediate for SUVpeak (12.0-16.0%), and highest for SUVmax (17.8-22.2%). Count reduction increased test-retest variance non-significantly (p > 0.05) for all SUV types and normalizations. For SUVpeak at 50% of counts, RCs remained < 30% when small lesions were excluded. Splitting data reduced CNR by median 4.6% (interquartile range 1.2-8.7%) and 4.6% (interquartile range 1.2-8.7%) for EARL1 and EARL2 images, respectively. CONCLUSIONS: Reducing [18F]FDHT PET acquisition time from 3 min to 1.5 per bed position resulted in a repeatability of SUVpeak (bodyweight) remaining ≤ 30%, which is generally acceptable for response monitoring purposes. However, EARL2 reconstruction was more affected, especially for SUVmax whose repeatability tended to exceed 30%. Lesion detectability was only slightly impaired by reducing acquisition time, which might not be clinically relevant in mCRPC.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Cysouw MCF, Kramer GM, Heijtel D, et al. Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer. EJNMMI Res. 2019. PMID: 31363939. doi:10.1186/s13550-019-0531-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。